1. Home
  2. GVH vs KPRX Comparison

GVH vs KPRX Comparison

Compare GVH & KPRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Globavend Holdings Limited

GVH

Globavend Holdings Limited

HOLD

Current Price

$1.01

Market Cap

10.7M

Sector

N/A

ML Signal

HOLD

Logo Kiora Pharmaceuticals Inc.

KPRX

Kiora Pharmaceuticals Inc.

HOLD

Current Price

$2.51

Market Cap

11.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
GVH
KPRX
Founded
2016
1998
Country
Australia
United States
Employees
N/A
N/A
Industry
Biotechnology: In Vitro & In Vivo Diagnostic Substances
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
10.7M
11.7M
IPO Year
2023
2014

Fundamental Metrics

Financial Performance
Metric
GVH
KPRX
Price
$1.01
$2.51
Analyst Decision
Strong Buy
Strong Buy
Analyst Count
1
1
Target Price
$80.00
$10.00
AVG Volume (30 Days)
1.1M
21.1K
Earning Date
02-17-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
$102,768.97
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$0.74
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.87
$1.76
52 Week High
$6.46
$2.99

Technical Indicators

Market Signals
Indicator
GVH
KPRX
Relative Strength Index (RSI) 32.11 43.81
Support Level $0.87 $2.43
Resistance Level $1.29 $2.61
Average True Range (ATR) 0.10 0.08
MACD 0.10 -0.00
Stochastic Oscillator 29.97 30.43

Price Performance

Historical Comparison
GVH
KPRX

About GVH Globavend Holdings Limited

Globavend Holdings Ltd is an e-commerce logistics provider, it provides integrated cross-border logistics services from Hong Kong to Australia and New Zealand, where it provides customers with a one-stop solution from parcel consolidation to air freight forwarding, customs clearance, on-carriage parcel transportation and delivery. It operates in logistics and freight forwarding industry, which involves the provision of services such as freight transport, freight forwarding, warehouse management, and distribution.

About KPRX Kiora Pharmaceuticals Inc.

Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.

Share on Social Networks: